An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ambrx Biopharma Inc. (NYSE: AMAM) has announced that Feng Tian, Ph.D., will present at two investor conferences in May. At the Bank of America 2022 Healthcare Conference, he will participate in a fireside chat on May 11 at 12:00 PM PT. Dr. Tian will also have a pre-recorded presentation at the H.C. Wainwright Global Investment Conference on May 24 at 4:00 AM PT. Interested parties can access the webcasts via www.Ambrx.com. Ambrx focuses on developing Engineered Precision Biologics for various therapeutic areas.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May.
Bank of America 2022 Healthcare Conference.Dr. Tian will participate in an analyst led fireside chat on Wednesday, May 11 at 12:00 PM Pacific Time / 3:00 PM Eastern Time.
H.C. Wainwright Global Investment Conference. Dr. Tian will conduct a pre-recorded presentation that will be available on-demand on Tuesday, May 24 at 4:00 AM Pacific Time / 7:00 AM Eastern Time.
Interested parties can access the live and pre-recorded webcasts for these conferences from the Investor Relations section of the company's website at www.Ambrx.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.
What conferences will Ambrx Biopharma present at in May 2022?
Ambrx Biopharma will present at the Bank of America 2022 Healthcare Conference on May 11 and the H.C. Wainwright Global Investment Conference on May 24.
When will Feng Tian present at the Bank of America Healthcare Conference?
Feng Tian will present at the Bank of America Healthcare Conference on May 11, 2022, at 12:00 PM Pacific Time.
What time is Feng Tian's presentation at the H.C. Wainwright Global Investment Conference?
Feng Tian's pre-recorded presentation at the H.C. Wainwright Global Investment Conference will be available on May 24, 2022, at 4:00 AM Pacific Time.
How can I access the webcasts for Ambrx presentations?
Webcasts for Ambrx presentations can be accessed through the Investor Relations section of their website at www.Ambrx.com.
What is Ambrx Biopharma known for?
Ambrx Biopharma is known for its expanded genetic code technology platform to develop Engineered Precision Biologics, including next-generation antibody drug conjugates and targeted therapies.
